What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?

The following factors were found to be independent predictors of better OS according to multivariate analysis (Table 3 b): good baseline WHO performance status, normal baseline albumin level, the resection of residual disease during imatinib therapy, the presence of exon 11 KIT mutations, and (with borderline significance) the maximal tumor diameter of the largest tumor >10 cm.

also in 7,017 other papers